首页 >
法规速递
-
Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Immunologicals Working Party (IWP) 2026-2025/12/12
2025-12-15查看详情 > -
Document: European Medicines Agency’s data protection notice for the EudraVigilance Signal and Safety Analytics (EV SSA) platform-2026/1/26
2026-01-27查看详情 > -
Document: Darwin EU: How often respiratory syncytial virus (RSV) affects different age groups in Europe-2026/3/4
2026-03-05查看详情 > -
Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle-2026/3/30
2026-04-02查看详情 > -
Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework-2026/5/13
2026-05-15查看详情 > -
Document: Concept paper on the revision of the guideline on the clinical evaluation of antifungal agents for the treatment and prophylaxis of invasive fungal disease-2026/6/29
2026-06-30查看详情 > -
Scientific guideline: Reflection paper on the criteria to be considered for the evaluation of new active substance (NAS) status of biological substances-2022/11/18
2022-11-30查看详情 > -
国家药品监督管理局批准硫酸氢司美替尼胶囊上市-2023/6/1
2023-06-01查看详情 > -
国家药监局药审中心关于发布《特应性皮炎治疗药物临床试验技术指导原则》的通告（2023年第58号）-2023/12/1
2023-12-04查看详情 > -
Document: Questions and answers to stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use-2025/1/21
2025-01-22查看详情 >
